Published in J Am Coll Cardiol on March 10, 2013
Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics | NCT02611596
Ranolazine: A Contemporary Review. J Am Heart Assoc (2016) 3.67
Development and validation of a short version of the Seattle angina questionnaire. Circ Cardiovasc Qual Outcomes (2014) 1.54
In regard to the TERISA trial. J Am Coll Cardiol (2014) 1.05
Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes. Diabetes Care (2015) 0.91
A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J (2015) 0.85
Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain. Eur J Health Econ (2014) 0.84
Angina treatments and prevention of cardiac events: an appraisal of the evidence. Eur Heart J Suppl (2015) 0.78
Mitochondrial dysfunction and its impact on diabetic heart. Biochim Biophys Acta (2016) 0.76
Inhibition of sarcolemmal FAT/CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia/reoxygenation. Cardiovasc Res (2017) 0.75
Reply: In regard to the TERISA trial. J Am Coll Cardiol (2014) 0.75
Update on ranolazine in the management of angina. Vasc Health Risk Manag (2014) 0.75
A Review of the Key Clinical Trials of 2015: Results and Implications. Cardiol Ther (2016) 0.75
Impact of angina frequency on health utility values of patients with chronic stable angina. Health Qual Life Outcomes (2014) 0.75
Ranolazine's sweet side--improvement of glycaemic control by the novel mechanism of skeletal muscle microvascular recruitment. J Physiol (2013) 0.75
Comparison of ranolazine and trimetazidine on glycemic status in diabetic patients with coronary artery disease - a randomized controlled trial. J Clin Diagn Res (2015) 0.75
Assessing Quality of Life and Medical Care in Chronic Angina: An Internet Survey. Interact J Med Res (2016) 0.75
Diabetes and coronary disease: a need for new therapies for an expanding disease burden. J Am Coll Cardiol (2013) 0.75
Good! Is it the best??? J Pharmacol Pharmacother (2013) 0.75
Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective. BMJ Open (2015) 0.75
Diabetes: Ranolazine decreases angina. Nat Rev Cardiol (2013) 0.75
Effects of the Mean Amplitude of Glycemic Excursions and Vascular Endothelial Dysfunction on Cardiovascular Events in Nondiabetic Patients With Coronary Artery Disease. J Am Heart Assoc (2017) 0.75
Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. Circ Cardiovasc Qual Outcomes (2017) 0.75
Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function. J Am Heart Assoc (2017) 0.75
Ranolazine promotes muscle differentiation and reduces oxidative stress in C2C12 skeletal muscle cells. Endocrine (2016) 0.75
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature (2012) 18.23
The Genome sequence of the SARS-associated coronavirus. Science (2003) 16.68
Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA (2003) 16.08
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Telemonitoring in patients with heart failure. N Engl J Med (2010) 10.82
Genome-wide association study of 107 phenotypes in Arabidopsis thaliana inbred lines. Nature (2010) 10.66
Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature (2007) 10.40
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science (2005) 8.20
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75
Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med (2011) 7.52
Modelling schizophrenia using human induced pluripotent stem cells. Nature (2011) 7.41
Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA (2007) 7.12
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55
A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A (2012) 6.27
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13
Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA (2010) 6.11
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
Trends in survival after in-hospital cardiac arrest. N Engl J Med (2012) 5.67
Characterization of human metapneumoviruses isolated from patients in North America. J Infect Dis (2002) 5.64
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21
A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature (2013) 5.18
Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. JAMA (2006) 5.06
B-type natriuretic peptide in cardiovascular disease. Lancet (2003) 4.80
Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science (2006) 4.71
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol (2002) 4.48
Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med (2006) 4.44
Appropriateness of percutaneous coronary intervention. JAMA (2011) 4.33
Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis (2004) 4.29
Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA (2009) 4.24
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol (2011) 4.16
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation (2004) 4.13
New world bats harbor diverse influenza A viruses. PLoS Pathog (2013) 4.10
Serum potassium levels and mortality in acute myocardial infarction. JAMA (2012) 4.09
Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA (2012) 4.04
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97
Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail (2009) 3.95
Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell (2005) 3.89
Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med (2010) 3.85
Long-term outcomes in elderly survivors of in-hospital cardiac arrest. N Engl J Med (2013) 3.85
Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell (2013) 3.81
Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation (2012) 3.61
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol (2003) 3.51
Race and gender differences in C-reactive protein levels. J Am Coll Cardiol (2005) 3.51
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45
AMPylation of Rho GTPases by Vibrio VopS disrupts effector binding and downstream signaling. Science (2008) 3.44
Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension (2006) 3.42
Automated external defibrillators and survival after in-hospital cardiac arrest. JAMA (2010) 3.36
Hospital-wide code rates and mortality before and after implementation of a rapid response team. JAMA (2008) 3.30
Human Bocavirus infection, Canada. Emerg Infect Dis (2006) 3.30
Hospital variation in time to defibrillation after in-hospital cardiac arrest. Arch Intern Med (2009) 3.27
Contraindicated initiation of β-blocker therapy in patients hospitalized for heart failure. JAMA Intern Med (2013) 3.26
Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther (2007) 3.26
Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature (2004) 3.24
Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation (2008) 3.19
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA (2005) 3.16
A Pseudomonas syringae effector inactivates MAPKs to suppress PAMP-induced immunity in plants. Cell Host Microbe (2007) 3.15
The scale of population structure in Arabidopsis thaliana. PLoS Genet (2010) 3.12
PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol (2014) 3.12
Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol (2002) 3.05
Triple reassortant H3N2 influenza A viruses, Canada, 2005. Emerg Infect Dis (2006) 3.05
The concept of risk in comparative-effectiveness research. N Engl J Med (2014) 3.04
Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis. Nat Biotechnol (2009) 3.01
Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation (2003) 3.01
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature (2013) 3.00
Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev (2006) 2.99